Alpha 2.0
Login Register
» Articles » PMID: 35773170

Sodium-glucose Cotransporter 2 Inhibitors Reduce Cardiovascular Events in Acute Heart Failure. A Real-world Analysis

Overview
Journal Eur J Intern Med
Specialty General Medicine
Date 2022 Jun 30
PMID 35773170
Authors
Raquel Lopez-Vilella
Victor Donoso Trenado
Borja Guerrero Cervera
Ignacio Sanchez-Lazaro
Luis Almenar Bonet
Affiliations
Soon will be listed here.
Citing Articles

Efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with acute heart failure: a systematic review and meta-analysis.

Hou J, Ren L, Hou Q, Jia X, Mei Z, Xu J Front Cardiovasc Med. 2024; 11:1388337.

PMID: 39323760 PMC: 11422105. DOI: 10.3389/fcvm.2024.1388337.

Progress of patients hospitalized with acute heart failure treated with empagliflozin.

Raya-Cruz M, Jurado J, de la Torre Peregrin G, Montufar N, Sanchez A, Delgado F J Comp Eff Res. 2024; 13(6):e240027.

PMID: 38785682 PMC: 11145528. DOI: 10.57264/cer-2024-0027.

Annual evolution of the prescription of drugs with prognostic implications in acute decompensated heart failure with reduced ejection fraction.

Lopez-Vilella R, DonosoTrenado V, Guerrero Cervera B, Sanchez-Lazaro I, Dolz L, Almenar Bonet L BMC Cardiovasc Disord. 2024; 24(1):105.

PMID: 38355445 PMC: 10865667. DOI: 10.1186/s12872-024-03728-y.

The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest.

Patoulias D, Fragakis N, Rizzo M Life (Basel). 2022; 12(12).

PMID: 36556427 PMC: 9782870. DOI: 10.3390/life12122062.